Vitamin D, Vitamin D Receptor, and Cathelicidin in the Treatment of Tuberculosis

Vitamins and Hormones

Volumn 86, Issue , 2011, Pages 307-325

  Selvaraj, P ^a  

^a INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

Author keywords

Cathelicidin; Tuberculosis; Vitamin D; Vitamin D receptor

Indexed keywords

ANTIMICROBIAL CATIONIC PEPTIDE; CALCITRIOL RECEPTOR; CAP18 LIPOPOLYSACCHARIDE BINDING PROTEIN; CAP18 LIPOPOLYSACCHARIDE-BINDING PROTEIN; TUBERCULOSTATIC AGENT; VITAMIN D;

ANIMAL; BIOSYNTHESIS; BOOK; DIET SUPPLEMENTATION; GENETIC VARIABILITY; GENETICS; HUMAN; IMMUNOMODULATION; MACROPHAGE; METABOLISM; MULTIMODALITY CANCER THERAPY; PHOTOTHERAPY; TUBERCULOSIS;

ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; ANTITUBERCULAR AGENTS; COMBINED MODALITY THERAPY; DIETARY SUPPLEMENTS; GENETIC VARIATION; HELIOTHERAPY; HUMANS; IMMUNOMODULATION; MACROPHAGES; RECEPTORS, CALCITRIOL; TUBERCULOSIS; VITAMIN D;

EID: 79952654281     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-386960-9.00013-7     Document Type: Book

References (104)

1. Agerberth B., Gunne H., Odeberg J., Kogner P., Boman H.G., Gudmundsson G.H. FALL-39, a putative human peptide antibiotic, is cysteine-free and expressed in bone marrow and testis. Proc. Natl. Acad. Sci. USA 1995, 92:195-199.
2. Agerberth B., Charo J., Werr J., Olsson B., Idali F., Lindbom L., Kiessling R., Jornvall H., Wigzell H., Gudmundsson G.H. The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. Blood 2000, 96:3086-3093.
3. Akeno N., Saikatsu S., Kawane T., Horiuchi N. Mouse vitamin D-24-hydroxylase: Molecular cloning, tissue distribution, and transcriptional regulation by 1alpha,25-dihydroxyvitamin D3. Endocrinology 1997, 138:2233-2240.
4. Alroy I., Towers T.L., Freedman L.P. Transcriptional repression of the interleukin-2 gene by vitamin D3: Direct inhibition of NFATp/AP-1 complex formation by a nuclear hormone receptor. Mol. Cell. Biol. 1995, 15:5789-5799.
5. Arai H., Miyamoto K.I., Yoshida M., Yamamoto H., Taketani Y., Morita K., Kubota M., Yoshida S., Ikeda M., Watabe F., Kanemasa Y., Takeda E. The polymorphism in the caudal-related homeodomain protein Cdx-2 binding element in the human vitamin D receptor gene. J. Bone Miner. Res. 2001, 16:1256-1264.
6. Armas L.A., Hollis B.W., Heaney R.P. Vitamin D2 is much less effective than vitamin D3 in humans. J. Clin. Endocrinol. Metab. 2004, 89:5387-5391.
7. Babb C., van der Merwe L., Beyers N., Pheiffer C., Walzl G., Duncan K., van Helden P., Hoal E.G. Vitamin D receptor gene polymorphisms and sputum conversion time in pulmonary tuberculosis patients. Tuberculosis (Edinb) 2007, 87:295-302.
8. Baker A.R., McDonnell D.P., Hughes M., Crisp T.M., Mangelsdorf D.J., Haussler M.R., Pike J.W., Shine J., O'Malley B.W. Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc. Natl. Acad. Sci. USA 1988, 85:3294-3298.
9. Bals R., Wang X., Zasloff M., Wilson J.M. The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc. Natl. Acad. Sci. USA 1998, 95:9541-9546.
10. Bensch K.W., Raida M., Magert H.J., Schulz-Knappe P., Forssmann W.G. hBD-1: A novel beta-defensin from human plasma. FEBS Lett. 1995, 368:331-335.
11. Bhalla A.K., Amento E.P., Krane S.M. Differential effects of 1,25-dihydroxyvitamin D3 on human lymphocytes and monocyte/macrophages: Inhibition of interleukin-2 and augmentation of interleukin-1 production. Cell. Immunol. 1986, 98:311-322.
12. Brincourt J. Does calciferol have a liquifying action on caseum?. Poumon Coeur 1967, 23:841-851.
13. Brincourt J. Liquefying effect on suppurations of an oral dose of calciferol. Presse Méd. 1969, 77:467-470.
14. Charpy J. Aspects of vitamin and functional substance therapy in dermatology. Bull. Méd. 1950, 64:555-559.
15. Chen S., Sims G.P., Chen X.X., Gu Y.Y., Chen S., Lipsky P.E. Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J. Immunol. 2007, 179:1634-1647.
16. Cheskis B., Freedman L.P. Ligand modulates the conversion of DNA-bound vitamin D3 receptor (VDR) homodimers into VDR-retinoid X receptor heterodimers. Mol. Cell. Biol. 1994, 14:3329-3338.
17. Cippitelli M., Santoni A. Vitamin D3: A transcriptional modulator of the interferon-gamma gene. Eur. J. Immunol. 1998, 28:3017-3030.
18. Cosma C.L., Sherman D.R., Ramakrishnan L. The secret lives of the pathogenic mycobacteria. Annu. Rev. Microbiol. 2003, 57:641-676.
19. Crowle A.J., Ross E.J., May M.H. Inhibition by 1,25(OH)2-vitamin D3 of the multiplication of virulent tubercle bacilli in cultured human macrophages. Infect. Immun. 1987, 55:2945-2950.
20. De Y., Chen Q., Schmidt A.P., Anderson G.M., Wang J.M., Wooters J., Oppenheim J.J., Chertov O. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J. Exp. Med. 2000, 192:1069-1074.
21. Di Nardo A., Vitiello A., Gallo R.L. Cutting edge: Mast cell antimicrobial activity is mediated by expression of cathelicidin antimicrobial peptide. J. Immunol. 2003, 170:2274-2278.
22. Dong X., Craig T., Xing N., Bachman L.A., Paya C.V., Weih F., McKean D.J., Kumar R., Griffin M.D. Direct transcriptional regulation of RelB by 1alpha,25-dihydroxyvitamin D3 and its analogs: Physiologic and therapeutic implications for dendritic cell function. J. Biol. Chem. 2003, 278:49378-49385.
23. Dowling G.B., Prosser Thomas E.W. Treatment of lupus vulgaris with calciferol. Lancet 1946, 1:919-922.
24. Dye C. Global epidemiology of tuberculosis. Lancet 2006, 367:938-940.
25. Faraco J.H., Morrison N.A., Baker A., Shine J., Frossard P.M. ApaI dimorphism at the human vitamin D receptor gene locus. Nucleic Acids Res. 1989, 17:2150.
26. Fielding J., Maloney J.J. Calciferol, streptomycin, and para-aminosalicylic acid in pulmonary tuberculosis. Lancet 1951, 2:614-617.
27. Frohm M., Agerberth B., Ahangari G., Stahle-Backdahl M., Liden S., Wigzell H., Gudmundsson G.H. The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders. J. Biol. Chem. 1997, 272:15258-15263.
28. Ganz T., Lehrer R.I. Defensins. Curr. Opin. Immunol. 1994, 6:584-589.
29. Gao L., Tao Y., Zhang L., Jin Q. Vitamin D receptor genetic polymorphisms and tuberculosis: Updated systematic review and meta-analysis. Int. J. Tuberc. Lung Dis. 2010, 14:15-23.
30. Gibney K.B., MacGregor L., Leder K., Torresi J., Marshall C., Ebeling P.R., Biggs B.A. Vitamin D deficiency is associated with tuberculosis and latent tuberculosis infection in immigrants from sub-Saharan Africa. Clin. Infect. Dis. 2008, 46:443-446.
31. Gombart A.F., Borregaard N., Koeffler H.P. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J. 2005, 19:1067-1077.
32. Grad R. Cod and the consumptive: A brief history of cod-liver oil in the treatment of pulmonary tuberculosis. Pharm. Hist. 2004, 46:106-120.
33. Griffin M.D., Dong X., Kumar R. Vitamin D receptor-mediated suppression of RelB in antigen presenting cells: A paradigm for ligand-augmented negative transcriptional regulation. Arch. Biochem. Biophys. 2007, 460:218-226.
34. Gross C., Eccleshall T.R., Malloy P.J., Villa M.L., Marcus R., Feldman D. The presence of a polymorphism at the translation initiation site of the vitamin D receptor gene is associated with low bone mineral density in postmenopausal Mexican-American women. J. Bone Miner. Res. 1996, 11:1850-1855.
35. Halsall J.A., Osborne J.E., Potter L., Pringle J.H., Hutchinson P.E. A novel polymorphism in the 1A promoter region of the vitamin D receptor is associated with altered susceptibility and prognosis in malignant melanoma. Br. J. Cancer 2004, 91:765-770.
36. Harant H., Andrew P.J., Reddy G.S., Foglar E., Lindley I.J. 1alpha,25-Dihydroxyvitamin D3 and a variety of its natural metabolites transcriptionally repress nuclear-factor-kappaB-mediated interleukin-8 gene expression. Eur. J. Biochem. 1997, 250:63-71.
37. Hill A.V. The immunogenetics of human infectious diseases. Annu. Rev. Immunol. 1998, 16:593-617.
38. Hill A.V. Immunogenetics and genomics. Lancet 2001, 357:2037-2041.
39. Hill A.V. Aspects of genetic susceptibility to human infectious diseases. Annu. Rev. Genet. 2006, 40:469-486.
40. Hmama Z., Sendide K., Talal A., Garcia R., Dobos K., Reiner N.E. Quantitative analysis of phagolysosome fusion in intact cells: Inhibition by mycobacterial lipoarabinomannan and rescue by an 1alpha,25-dihydroxyvitamin D3-phosphoinositide 3-kinase pathway. J. Cell Sci. 2004, 117:2131-2140.
41. Holick M.F. Vitamin D deficiency. N. Engl. J. Med. 2007, 357:266-281.
42. Houben E.N., Nguyen L., Pieters J. Interaction of pathogenic mycobacteria with the host immune system. Curr. Opin. Microbiol. 2006, 9:76-85.
43. Hustmyer F.G., DeLuca H.F., Peacock M. ApaI, BsmI, EcoRV and TaqI polymorphisms at the human vitamin D receptor gene locus in Caucasians, blacks and Asians. Hum. Mol. Genet. 1993, 2:487.
44. Karlsson J., Carlsson G., Larne O., Andersson M., Putsep K. Vitamin D3 induces pro-LL-37 expression in myeloid precursors from patients with severe congenital neutropenia. J. Leukoc. Biol. 2008, 84:1279-1286.
45. Kaufmann S.H. Tuberculosis: Back on the immunologists' agenda. Immunity 2006, 24:351-357.
46. Kim S., Shevde N.K., Pike J.W. 1,25-Dihydroxyvitamin D3 stimulates cyclic vitamin D receptor/retinoid X receptor DNA-binding, co-activator recruitment, and histone acetylation in intact osteoblasts. J. Bone Miner. Res. 2005, 20:305-317.
47. Kliewer S.A., Umesono K., Mangelsdorf D.J., Evans R.M. Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Nature 1992, 355:446-449.
48. Lemire J.M., Adams J.S., Sakai R., Jordan S.C. 1 alpha,25-Dihydroxyvitamin D3 suppresses proliferation and immunoglobulin production by normal human peripheral blood mononuclear cells. J. Clin. Invest. 1984, 74:657-661.
49. Liu P.T., Stenger S., Li H., Wenzel L., Tan B.H., Krutzik S.R., Ochoa M.T., Schauber J., Wu K., Meinken C., Kamen D.L., Wagner M., et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006, 311:1770-1773.
50. Liu P.T., Stenger S., Tang D.H., Modlin R.L. Cutting edge: Vitamin D-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin. J. Immunol. 2007, 179:2060-2063.
51. Malloy P.J., Eccleshall T.R., Gross C., Van Maldergem L., Bouillon R., Feldman D. Hereditary vitamin D resistant rickets caused by a novel mutation in the vitamin D receptor that results in decreased affinity for hormone and cellular hyporesponsiveness. J. Clin. Invest. 1997, 99:297-304.
52. Martineau A.R., Honecker F.U., Wilkinson R.J., Griffiths C.J. Vitamin D in the treatment of pulmonary tuberculosis. J. Steroid Biochem. Mol. Biol. 2007, 103:793-798.
53. Martineau A.R., Wilkinson K.A., Newton S.M., Floto R.A., Norman A.W., Skolimowska K., Davidson R.N., Sorensen O.E., Kampmann B., Griffiths C.J., Wilkinson R.J. IFN-gamma- and TNF-independent vitamin D-inducible human suppression of mycobacteria: The role of cathelicidin LL-37. J. Immunol. 2007, 178:7190-7198.
54. Martineau A.R., Wilkinson R.J., Wilkinson K.A., Newton S.M., Kampmann B., Hall B.M., Packe G.E., Davidson R.N., Eldridge S.M., Maunsell Z.J., Rainbow S.J., Berry J.L., et al. A single dose of vitamin D enhances immunity to mycobacteria. Am. J. Respir. Crit. Care Med. 2007, 176:208-213.
55. Martineau A.R., Leandro A.C., Anderson S.T., Newton S.M., Wilkinson K.A., Nicol M.P., Pienaar S.M., Skolimowska K.H., Rocha M.A., Rolla V.C., Levin M., Davidson R.N., et al. Association between Gc genotype and susceptibility to TB is dependent on vitamin D status. Eur. Respir. J. 2009, 35:1106-1112.
56. Martineau A.R., Nanzer A.M., Satkunam K.R., Packe G.E., Rainbow S.J., Maunsell Z.J., Timms P.M., Venton T.R., Eldridge S.M., Davidson R.N., Wilkinson R.J., Griffiths C.J. Influence of a single oral dose of vitamin D(2) on serum 25-hydroxyvitamin D concentrations in tuberculosis patients. Int. J. Tuberc. Lung Dis. 2009, 13:119-125.
57. Matsui T., Nakao Y., Koizumi T., Nakagawa T., Fujita T. 1,25-Dihydroxyvitamin D3 regulates proliferation of activated T-lymphocyte subsets. Life Sci. 1985, 37:95-101.
58. McKenna N.J., Lanz R.B., O'Malley B.W. Nuclear receptor coregulators: Cellular and molecular biology. Endocr. Rev. 1999, 20:321-344.
59. Meehan M.A., Kerman R.H., Lemire J.M. 1,25-Dihydroxyvitamin D3 enhances the generation of nonspecific suppressor cells while inhibiting the induction of cytotoxic cells in a human MLR. Cell. Immunol. 1992, 140:400-409.
60. Misawa Y., Baba A., Ito S., Tanaka M., Shiohara M. Vitamin D(3) induces expression of human cathelicidin antimicrobial peptide 18 in newborns. Int. J. Hematol. 2009, 90:561-570.
61. Miyamoto K., Kesterson R.A., Yamamoto H., Taketani Y., Nishiwaki E., Tatsumi S., Inoue Y., Morita K., Takeda E., Pike J.W. Structural organization of the human vitamin D receptor chromosomal gene and its promoter. Mol. Endocrinol. 1997, 11:1165-1179.
62. Morcos M.M., Gabr A.A., Samuel S., Kamel M., el Baz M., el Beshry M., Michail R.R. Vitamin D administration to tuberculous children and its value. Boll. Chim. Farm. 1998, 137:157-164.
63. Morrison N.A., Yeoman R., Kelly P.J., Eisman J.A. Contribution of trans-acting factor alleles to normal physiological variability: Vitamin D receptor gene polymorphism and circulating osteocalcin. Proc. Natl. Acad. Sci. USA 1992, 89:6665-6669.
64. Morrison N.A., Qi J.C., Tokita A., Kelly P.J., Crofts L., Nguyen T.V., Sambrook P.N., Eisman J.A. Prediction of bone density from vitamin D receptor alleles. Nature 1994, 367:284-287.
65. Muller K., Bendtzen K. Inhibition of human T lymphocyte proliferation and cytokine production by 1,25-dihydroxyvitamin D3. Differential effects on CD45RA+ and CD45R0+ cells. Autoimmunity 1992, 14:37-43.
66. Narang N.K., Gupta R.C., Jain M.K. Role of vitamin D in pulmonary tuberculosis. J. Assoc. Physicians India 1984, 32:185-188.
67. Nnoaham K.E., Clarke A. Low serum vitamin D levels and tuberculosis: A systematic review and meta-analysis. Int. J. Epidemiol. 2008, 37:113-119.
68. Nursyam E.W., Amin Z., Rumende C.M. The effect of vitamin D as supplementary treatment in patients with moderately advanced pulmonary tuberculous lesion. Acta Med. Indones. 2006, 38:3-5.
69. Ohta M., Okabe T., Ozawa K., Urabe A., Takaku F. 1 alpha,25-Dihydroxyvitamin D3 (calcitriol) stimulates proliferation of human circulating monocytes in vitro. FEBS Lett. 1985, 185:9-13.
70. Penna G., Adorini L. 1 alpha,25-Dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J. Immunol. 2000, 164:2405-2411.
71. Pinette K.V., Yee Y.K., Amegadzie B.Y., Nagpal S. Vitamin D receptor as a drug discovery target. Mini Rev. Med. Chem. 2003, 3:193-204.
72. Prabhu Anand S., Selvaraj P., Narayanan P.R. Effect of 1,25 dihydroxyvitamin D3 on intracellular IFN-gamma and TNF-alpha positive T cell subsets in pulmonary tuberculosis. Cytokine 2009, 45:105-110.
73. Range N., Changalucha J., Krarup H., Magnussen P., Andersen A.B., Friis H. The effect of multi-vitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: A randomised two-by-two factorial trial in Mwanza, Tanzania. Br. J. Nutr. 2006, 95:762-770.
74. Reichel H., Koeffler H.P., Tobler A., Norman A.W. 1 alpha,25-Dihydroxyvitamin D3 inhibits gamma-interferon synthesis by normal human peripheral blood lymphocytes. Proc. Natl. Acad. Sci. USA 1987, 84:3385-3389.
75. Rigby W.F., Stacy T., Fanger M.W. Inhibition of T lymphocyte mitogenesis by 1,25-dihydroxyvitamin D3 (calcitriol). J. Clin. Invest. 1984, 74:1451-1455.
76. Rivas-Santiago B., Hernandez-Pando R., Carranza C., Juarez E., Contreras J.L., Aguilar-Leon D., Torres M., Sada E. Expression of cathelicidin LL-37 during Mycobacterium tuberculosis infection in human alveolar macrophages, monocytes, neutrophils, and epithelial cells. Infect. Immun. 2008, 76:935-941.
77. Rockett K.A., Brookes R., Udalova I., Vidal V., Hill A.V., Kwiatkowski D. 1,25-Dihydroxyvitamin D3 induces nitric oxide synthase and suppresses growth of Mycobacterium tuberculosis in a human macrophage-like cell line. Infect. Immun. 1998, 66:5314-5321.
78. Roelandts R. The history of phototherapy: Something new under the sun?. J. Am. Acad. Dermatol. 2002, 46:926-930.
79. Rook G.A., Steele J., Fraher L., Barker S., Karmali R., O'Riordan J., Stanford J. Vitamin D3, gamma interferon, and control of proliferation of Mycobacterium tuberculosis by human monocytes. Immunology 1986, 57:159-163.
80. Rosenberg I.H. Challenges and opportunities in the translation of the science of vitamins. Am. J. Clin. Nutr. 2007, 85:325S-327S.
81. Roth D.E., Soto G., Arenas F., Bautista C.T., Ortiz J., Rodriguez R., Cabrera L., Gilman R.H. Association between vitamin D receptor gene polymorphisms and response to treatment of pulmonary tuberculosis. J. Infect. Dis. 2004, 190:920-927.
82. Russell D.G. Mycobacterium tuberculosis: Here today, and here tomorrow. Nat. Rev. Mol. Cell Biol. 2001, 2:569-577.
83. Sasidharan P.K., Rajeev E., Vijayakumari V. Tuberculosis and vitamin D deficiency. J. Assoc. Physicians India 2002, 50:554-558.
84. Schauber J., Dorschner R.A., Coda A.B., Buchau A.S., Liu P.T., Kiken D., Helfrich Y.R., Kang S., Elalieh H.Z., Steinmeyer A., Zugel U., Bikle D.D., et al. Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. J. Clin. Invest. 2007, 117:803-811.
85. Scott M.G., Davidson D.J., Gold M.R., Bowdish D., Hancock R.E. The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. J. Immunol. 2002, 169:3883-3891.
86. Segaert S. Vitamin D regulation of cathelicidin in the skin: Toward a renaissance of vitamin D in dermatology?. J. Invest. Dermatol. 2008, 128:773-775.
87. Selvaraj P., Chandra G., Jawahar M.S., Rani M.V., Rajeshwari D.N., Narayanan P.R. Regulatory role of vitamin D receptor gene variants of Bsm I, Apa I, Taq I, and Fok I polymorphisms on macrophage phagocytosis and lymphoproliferative response to mycobacterium tuberculosis antigen in pulmonary tuberculosis. J. Clin. Immunol. 2004, 24:523-532.
88. Selvaraj P., Prabhu Anand S., Harishankar M., Alagarasu K. Plasma 1,25 dihydroxy vitamin D3 level and expression of vitamin d receptor and cathelicidin in pulmonary tuberculosis. J. Clin. Immunol. 2009, 29:470-478.
89. Sharma O.P. Hypercalcemia in granulomatous disorders: A clinical review. Curr. Opin. Pulm. Med. 2000, 6:442-447.
90. Sigmundsdottir H., Pan J., Debes G.F., Alt C., Habtezion A., Soler D., Butcher E.C. DCs metabolize sunlight-induced vitamin D3 to 'program' T cell attraction to the epidermal chemokine CCL27. Nat. Immunol. 2007, 8:285-293.
91. Sorensen O.E., Follin P., Johnsen A.H., Calafat J., Tjabringa G.S., Hiemstra P.S., Borregaard N. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood 2001, 97:3951-3959.
92. Taymans S.E., Pack S., Pak E., Orban Z., Barsony J., Zhuang Z., Stratakis C.A. The human vitamin D receptor gene (VDR) is localized to region 12cen-q12 by fluorescent in situ hybridization and radiation hybrid mapping: Genetic and physical VDR map. J. Bone Miner. Res. 1999, 14:1163-1166.
93. Trautwein H., Stein E. Vitamin D2 and pulmonary tuberculosis; effects and therapeutic results. Beitr. Klin. Tuberk. Spezif. Tuberkuloseforsch. 1952, 107:295-313.
94. Turner J., Cho Y., Dinh N.N., Waring A.J., Lehrer R.I. Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob. Agents Chemother. 1998, 42:2206-2214.
95. Ustianowski A., Shaffer R., Collin S., Wilkinson R.J., Davidson R.N. Prevalence and associations of vitamin D deficiency in foreign-born persons with tuberculosis in London. J. Infect. 2005, 50:432-437.
96. van Etten E., Mathieu C. Immunoregulation by 1,25-dihydroxyvitamin D3: Basic concepts. J. Steroid Biochem. Mol. Biol. 2005, 97:93-101.
97. Veldman C.M., Cantorna M.T., DeLuca H.F. Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. Arch. Biochem. Biophys. 2000, 374:334-338.
98. Vidyarani M., Selvaraj P., Jawahar M.S., Narayanan P.R. 1,25 Dihydroxyvitamin D3 modulated cytokine response in pulmonary tuberculosis. Cytokine 2007, 40:128-134.
99. Wang T.T., Nestel F.P., Bourdeau V., Nagai Y., Wang Q., Liao J., Tavera-Mendoza L., Lin R., Hanrahan J.W., Mader S., White J.H. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J. Immunol. 2004, 173:2909-2912.
100. Wejse C., Gomes V.F., Rabna P., Gustafson P., Aaby P., Lisse I.M., Andersen P.L., Glerup H., Sodemann M. Vitamin D as supplementary treatment for tuberculosis: A double-blind, randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 2009, 179:843-850.
101. Global Tuberculosis Control-Surveillance, Planning, Financing. WHO Report 2008 2008, World Health Organization, World Health Organization, Geneva.
102. Yim J.J., Selvaraj P. Genetic susceptibility in tuberculosis. Respirology 2010, 15:241-256.
103. Yuk J.M., Shin D.M., Lee H.M., Yang C.S., Jin H.S., Kim K.K., Lee Z.W., Lee S.H., Kim J.M., Jo E.K. Vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin. Cell Host Microbe 2009, 6:231-243.
104. Zasloff M. Fighting infections with vitamin D. Nat. Med. 2006, 12:388-390.